pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

Development 52

Development Drugs Clinical Development Antibody 52

The Pharma Data

JANUARY 31, 2021

In its Phase 1 clinical trial, Clover’s protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either Dynavax or GlaxoSmithKline plc (GSK, London Stock Exchange: GSK) both performed well and induced high levels of neutralizing antibodies while demonstrating favorable safety and tolerability profiles.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice).

Antibody 52

Antibody In-Vitro Trials Development 52

Drug Discovery World

JUNE 14, 2023

We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours. I started as a cancer biologist and worked with small molecules and antibodies. I’ve been with a company for more than five years now. This is not how I started out.

Research 52

Research Engineer In-Vivo Production 52

XTalks

FEBRUARY 27, 2024

Given the significant unmet needs in the advanced melanoma community, we are proud to offer a personalized, one-time therapeutic option for these patients.” Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.”

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Roots Analysis

SEPTEMBER 13, 2023

Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Development 40

Development Antibody Protein Drug Delivery Systems 40

XTalks

AUGUST 17, 2020

Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. The design of the immune biologic puts these elements together on an antibody scaffold. With the Neo-STAT platform, “it’s like making a separate antibody molecule for each one of those. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

AUGUST 23, 2021

But studies investigating both classes of drugs in combination must also consider the potential that the tau-targeting agent might only receive approval to be prescribed alongside an anti-amyloid antibody like aducanumab. With a $56,000 price tag for a year’s worth of treatment, Aduhelm is far from the most expensive drug on the market.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Delveinsight

DECEMBER 3, 2020

Roche receives FDA authorization for the quantitative COVID-19 antibody test. Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Merck chooses TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed. .” About Cytiva.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

pharmaphorum

DECEMBER 2, 2020

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The New York-based firm has requested approval for the combination of its anti-CD20 antibody ublituximab and umralisib, an oral drug that inhibits PI3K-delta and CK-1 epsilon.

Drugs 52

Drugs Trials Antibody Marketing 52

XTalks

JANUARY 19, 2024

Therapeutic radiopharmaceuticals are particularly used in the treatment of cancer. Therapeutic radiopharmaceuticals deliver beta or alpha radiation, which destroys diseased cells, such as cancer cells. billion influx into radiopharmaceuticals which underscores the potential and robust growth in this therapeutic area.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

MAY 5, 2021

India approves Roche/Regeneron antibody cocktail to treat COVID-19 ( Reuters ). Adagio offers first peek at Covid-19 antibody data, with preventative numbers that may rival mRNA vaccines ( Endpoints ). FDA approves 100th monoclonal antibody product ( Nature Reviews Drug Discovery ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

The Pharma Data

MAY 4, 2021

Frank D’Amelio, Chief Financial Officer and Executive Vice President, Global Supply, stated: “I am very happy with the performance of all of our therapeutic areas this quarter. Each of these accomplishments further demonstrates our commitment to Pfizer’s purpose: Breakthroughs that change patients’ lives.”. Pfizer recorded $1.0

Vaccination 40

Vaccination Vaccine Production Sales 40